Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01804036 · ClinicalTrials.gov registry record · Phase 2

Two Contrasting Interventions for Sleep Management

A Phase 2 study of Primary Insomnia and Secondary Insomnia, sponsored by University of Utah.

Completed
Registry status
Phase 2
Development phase
72
Enrollment target
2
Study locations

NCT01804036 is a Phase 2 study of Primary Insomnia and Secondary Insomnia that has completed, run by University of Utah. The registered enrollment target is 72 participants, below the 120-participant average among 12 other Primary Insomnia trials with a reported enrollment target (40% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01804036, a Phase 2 study of Primary Insomnia and Secondary Insomnia, has completed, sponsored by University of Utah.

COMPLETED
Registry status
Phase 2
Development phase
72 participants
Enrollment target
2
Study locations

Study Summary

This study will determine whether Mind-Body Bridging (MBB), a mindfulness training program is more effective than a common sleep medication, Zolpidem, in treating insomnia. It will also investigate whether MBB is additionally beneficial for co-morbid conditions such as stress, PTSD, depression, etc, compared with that of Zolpidem.

Interventions

  • DRUG Zolpidem
  • BEHAVIORAL Mind-Body Bridging

Study Locations (2)

Colorado

  • Evans Army Community Hospital - Colorado Springs

Utah

  • University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2013-03
Est. Completion 2016-11
Phase Phase 2

Sponsor

University of Utah

818 total trials

What the Registry Record Tells You About NCT01804036

The ClinicalTrials.gov registry entry for NCT01804036 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 120-participant average among 12 other Primary Insomnia trials with a reported enrollment target (40% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Primary Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Zolpidem is the first listed.

NCT01804036 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Colorado, Utah.

Frequently Asked Questions

What is clinical trial NCT01804036 about?

NCT01804036 is a clinical study titled "Two Contrasting Interventions for Sleep Management". This study will determine whether Mind-Body Bridging (MBB), a mindfulness training program is more effective than a common sleep medication, Zolpidem, in treating insomnia. It will also investigate whether MBB is additionally beneficial for co-morbid conditions such as stress, PTSD, depression, etc,...

What is the current status of trial NCT01804036?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2013-03. Estimated completion is 2016-11.

What conditions does trial NCT01804036 study?

This clinical trial studies the following conditions: Primary Insomnia, Secondary Insomnia.

What interventions are being tested in trial NCT01804036?

The interventions under investigation include: Zolpidem (DRUG), Mind-Body Bridging (BEHAVIORAL).

Who is sponsoring clinical trial NCT01804036?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01804036 being conducted?

This trial has 2 study locations across Colorado, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Primary Insomnia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.